ClinicalTrials.gg
Active, not recruitingNCT05041491BURST2DUpdated Nov 19, 2026

Breaking up Sedentary Time to Improve Glucose Control in a Population at Risk for Developing Type 2 Diabetes

An Early Phase 1 interventional study of BREAK and ONE in Pre-diabetes, sponsored by University of Colorado, Denver. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by University of Colorado, Denver · Early Phase 1, Interventional, and Prevention

How we know

Updated Nov 19, 2026Now Active, not recruitingPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
66
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 350 studies in Glucose Intolerance with a site in United States — 43 open to participants now, 65 under way, none of them phase 3. Glucose Intolerance · United States.

Planned enrollment
122nd of 307
66 · median 50
Started
2021
with 24 others
Phase 1
16 of 350
1 open now
Primary completion
2026-12
later than 23 of 64 live
Registered
265th of 350
by date

Among the 350 studies in Glucose Intolerance with a site in United States, this one is the 122nd largest by planned enrollment of the 307 interventional ones that give a count, is one of 25 that started in 2021, is one of 16 in phase 1, reaches primary completion later than 23 of the 64 other live ones, and was the 265th registered.

Glucose Intolerance

793 studies on the registry are indexed under Glucose Intolerance; 113 are open to participants now.

Browse Glucose Intolerance studies →

Open to participants now

43 of the 350 studies in Glucose Intolerance with a site in United States are open now. Recruiting first, the newest first:

38 more — sign in →

All 43 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 68 Glucose Intolerance studies recruiting now, 13 (19%) set no upper age limit and 50 (74%) stop at 75 or younger; 9 take children under 18; 32 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 350 studies in Glucose Intolerance with a site in United States, or all of them as a file.
02

Study summary

Newly released guidelines recommend increased physical activity (PA) and reduced sedentary behaviors (SB) to improve glycemia and prevent the onset and progression of type 2 diabetes (T2D). Typically, 30-60 min bouts of PA are advocated per day. Although this approach increases PA, it does not decrease the length of the sedentary periods through the day. This is important because recent epidemiological data suggest that frequently interrupting sedentary time improves glucose control even in people who achieve the recommended levels of PA. Preliminary experimental data suggest that breaking up prolonged sedentary time by performing multiple short bouts (5 min) of PA throughout the day, may improve glycemia more than performing a single continuous bout of PA, and thereby potentially be a novel strategy to prevent T2D. The improvement in glycemia was observed even when the total amount of PA and total energy expenditure were matched, suggesting that how and when PA is performed over the day may matter more than how much PA is done. However, important gaps in knowledge remain including: (1) whether similar benefits on glucose control would be observed in adults with prediabetes, a clinically relevant population that is at high risk of developing T2D; (2) whether these effects are sustained or diluted over time, and (3) what are the mechanistic underpinnings. To address these gaps, the investigators propose to measure the acute and chronic effects of PA breaks on glucose control and the underlying mechanisms in individuals at risk of developing T2D. Sedentary men and women with prediabetes (n=66, 50% F) will be randomized to either an intervention designed to interrupt SB with 5-min bouts of brisk walking performed hourly for 9 hours/day, 5 days/week (BREAK) or a control condition consisting of 45-min of brisk walking performed as a single daily continuous bout, 5 days/week (ONE). The two 3-months interventions will be matched for total active time.

03

Conditions studied

  • Pre-diabetes

Keywords

  • sedentary behavior
  • physical activity
  • glucose control
  • metabolism
  • pre-diabetes
04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female
  • of 18.5-40 kg/m2 and weight stable over the previous 6 months.
  • Age, 18-64 years old.
  • Fasting glucose of 100-125 mg/dL or fasting of 5.7-6.4%, or 2h OGTT blood glucose of 140-199mg/dL based on the American Diabetes Association criteria for pre-diabetes. Fasting glucose, HbA1c and OGTT results ordered by the participant's provider within 3-months of the screening visit will be accepted, provided they fall within the measurement of error range established by the institution's lab standards. Additionally, consistent use of Metformin (1 year) to prevent prediabetes from developing diabetes will be accepted.
  • Less than 150 minutes of moderate-to-vigorous physical activity (MVPA) per week and more than 6 hours of sitting time per day, as self-reported by the volunteers using the International Physical Activity Questionnaire (IPAQ).
  • Less than 6500 of steps per day as measured by a pedometer over 5 days (at least 1 weekend day).
  • Passing medical and physical screening, and analysis of blood and urine screening samples.
  • Low-moderate caffeine use (\<3 cups/day).
  • Agree to refrain from any other structured exercise than the physical activity prescribed in each arm of the study.
  • Agree to eat control diets for 3 days before and during the Clinical and Translational Research Center (CTRC) visits;
  • Agree to refrain from taking any over-the-counter (including nonsteroidal anti-inflammatory drugs) or prescribed medication (apart from oral ) for 3 days prior to the inpatient CTRC visits;
  • Agree to wear a Fitbit® activity monitor and upload data on the website on a daily basis for the whole duration of the study.
  • Agree to follow the physical activity interventions and to be randomly assigned to one of the two arms of the study.
  • Agree to complete all the study procedures.

Exclusion criteria

Exclusion Criteria:

  • Pregnancy, breast-feeding or for women.
  • Being considered unsafe to participate as determined by the study physician.
  • Ever having a history of systemic, psychiatric, neurological disease, or drug and alcohol abuse.
  • History of cardiovascular disease, diabetes, uncontrolled hypertension, untreated thyroid, renal, hepatic diseases, dyslipidemia or any other medical condition affecting weight or lipid metabolism.
  • Being positive for or or C.
  • Taking medications affecting weight, triglycerides, energy intake/energy expenditure, or sleep in the last 3 months.
  • Having abnormal blood chemistry and/or hematology as deemed significant by the study physician.
  • Being a smoker or having been a smoker in the 3 months prior to their screening visit.
  • Having donated over 400 mL of blood within 3 months (90 days) of screening for the study;
  • Working night shifts within 1 month of and throughout the study.
  • Not completing the trial days of BREAK and ONE during the screening period to assess the willingness and ability of the participant to perform each of the interventions.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Early Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
66 participants (estimated)

Study arms

  • Experimental
    BREAK Intervention

    Participants in the BREAK condition will perform 5-minute bouts of brisk walking hourly for 9 hours/day, 5 days/week for 3 months.

    Behavioral: BREAK

  • Active comparator
    ONE Intervention

    Participants in the ONE condition will perform 45 minutes of brisk walking as a single continuous bout, 5 days/week for 3 months.

    Behavioral: ONE

Interventions

  • BehavioralBREAK

    The BREAK intervention is a physical activity regimen.

  • BehavioralONE

    The ONE intervention is a physical activity regimen.

06

What researchers measure

Primary outcomes

  1. Glycemia

    Plasma glucose concentration in mg/dL measured before and 30, 60, 90 and 120 min after an oral glucose tolerance test (OGTT, 75g glucose).

    Time frame: Glucose concentration in mg/dl, measured at fasting, during a 2 hour OGTT and after

Secondary outcomes

  1. Insulinemia

    Plasma insulin concentration in milli-international units per milliliter (mUI/mL) measured before and 30, 60, 90 and 120 min after an oral glucose tolerance test (OGTT, 75g glucose).

    Time frame: Plasma insulin concentration in mUI/mL, measured at fasting, during a 2 hour OGTT and after

  2. Mean interstitial glucose concentration

    Mean interstitial glucose concentration measured continuously by a glucose monitor placed on the tricep for 24hours for 10 days.

    Time frame: Before and after 1 month and 3 months of intervention

  3. Daily glycemia variability

    Standard deviation (SD) of interstitial glucose concentration measured continuously by a glucose monitor placed on the tricep 24hours throughout 10 days.

    Time frame: Before and after 1 month and 3 months of intervention

  4. Fasting A1c concentration

    Fasting A1c concentration expressed in %

    Time frame: Time Frame: Before and after 1 month and 3 months of intervention

  5. Fasting fructosamine concentration

    Fasting fructosamine concentration in umol/L

    Time frame: Before and after 1 month and 3 months of intervention

  6. 12-hour exogenous glucose oxidation

    Rates of carbon-13 (13C) recovery (% of the dose) in expired carbon dioxide (CO2) following the ingestion of U-13C-glucose in both breakfast and lunch meals.

    Time frame: Before and after 1 month of intervention

  7. 12-hour endogenous glucose oxidation

    Rates of D2 recovery (% of the dose) in expired urines following the infusion of (2,2H2) glucose.

    Time frame: Before and after 1 month of intervention

  8. 12 hour CO2 production

    CO2 production measured by indirect calorimetry (ParvoMedics TrueOne® 2400, Salt Lake City) for 20 minutes every hour from 0800h to 1800h.

    Time frame: Before and after 1 month of intervention

  9. 12 hour O2 production

    O2 production measured by indirect calorimetry (ParvoMedics TrueOne 2400, Salt Lake City) for 20 minutes every hour from 0800h to 1800h.

    Time frame: Before and after 1 month of intervention

  10. 12 Urine excretion

    Urine will be measured every hour from 0730h to 1830h

    Time frame: Before and after 1 month of intervention

  11. Glucose kinetics

    Steele's equation for non-steady-state will be used to compute rate of appearance of total glucose (RaT) and rate of appearance of exogenous glucose (RaE), as well as the rates of disappearance (RdT and RdE) from the percentage of \[6,6-2H2\]glucose6 and of 13C-glucose in plasma glucose61. Endogenous glucose production (EGP) will be computed as RaT-RaE. Nonoxidative glucose disposal (NOGD) will be calculated by subtracting total carbohydrate oxidation from (RdT + RdE). Plasma glucose utilization will be assumed to be equivalent to RdT as has been confirmed previously. Muscle glycogen utilization during the active period will be calculated as total carbohydrate utilization during exercise minus plasma glucose utilization during exercise.

    Time frame: Before and after 1 month of intervention

  12. Fasting and postprandial glucose

    Fasting and postprandial glucose in mg/dl measured in response to standard lunch

    Time frame: Before and after 1 month of intervention

  13. Fasting and postprandial insulin

    Fasting and postprandial insulin in ml/iu measured in response to standard lunch

    Time frame: Before and after 1 month of intervention

  14. Fasting and postprandial C-Peptide

    Fasting and postprandial C-peptide nmol/mL measured in response to standard lunch

    Time frame: Before and after 1 month of intervention

  15. Fasting and postprandial glucagon

    Fasting and postprandial glucagon in pg/mL measured in response to standard lunch

    Time frame: Before and after 1 month of intervention

  16. Fasting and postprandial catecholamines

    Fasting and postprandial catecholamines in pg/mL measured in response to standard lunch

    Time frame: Before and after 1 month of intervention

  17. Skeletal muscle content of protein kinase B (Akt) (Aktser473/total)

    Vastus lateralis skeletal muscle biopsies will be collected from fasting participants by the Bergstrom technique. Biopsies will be used to measure protein kinase B (Akt) (Aktser473/total) using western blotting.

    Time frame: Before and after 1 month of intervention

  18. Skeletal muscle content of ACC (ACCS79/ total)

    Vastus lateralis skeletal muscle biopsies will be collected from fasting participants by the Bergstrom technique. Biopsies will be used to measure ACC (ACCS79/ total) using western blotting.

    Time frame: Before and after 1 month of intervention

  19. Skeletal muscle content of TBC1D4 (AS160/ total)

    Vastus lateralis skeletal muscle biopsies will be collected from fasting participants by the Bergstrom technique. Biopsies will be used to measure TBC1D4 (AS160/ total) using western blotting.

    Time frame: Before and after 1 month of intervention

  20. Skeletal muscle content of COX4

    Vastus lateralis skeletal muscle biopsies will be collected from fasting participants by the Bergstrom technique. Biopsies will be used to measure citrate synthase (COX4) using western blotting.

    Time frame: Before and after 1 month of intervention

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Nov 2021 (actual). Primary completion is estimated for Dec 2026, 60 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 19, 2026: primary completion May 2026 → Dec 2026 and completion Nov 2026 → Dec 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 26, 2021
First posted
Sep 13, 2021
StartActual
Nov 30, 2021
Primary completionEst.
Dec 15, 2026was May 2026
CompletionEst.
Dec 30, 2026was Nov 2026
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Nov 19, 2026
Primary completion
May 15, 2026→Dec 15, 2026
Nov 19, 2026
Study completion
Nov 30, 2026→Dec 30, 2026
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    Recruiting→Active, not recruiting
    Primary completion May 15, 2026→Dec 15, 2026
    Study completion Nov 30, 2026→Dec 30, 2026
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05041491
Responsible party
Sponsor
First posted
Sep 13, 2021
Start date
Nov 30, 2021
Primary completion
Dec 15, 2026 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
Nov 19, 2026

Study contacts

Audrey Bergouignan, PhD
principal investigator · University of Colorado, Denver

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion